

Crumlin Road Pharmacy Limited
Abridged Unaudited Financial Statements
for the financial year ended 31 March 2025

Crumlin Road Pharmacy Limited

CONTENTS

	Page
Directors' Responsibilities Statement	3
Balance Sheet	4
Statement of Changes in Equity	5
Notes to the Financial Statements	6 - 10

Crumlin Road Pharmacy Limited

DIRECTORS' RESPONSIBILITIES STATEMENT

for the financial year ended 31 March 2025

The directors made the following statement in respect of the unaudited financial statements:

"General responsibilities

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Directors' declaration on unaudited financial statements

In relation to the financial statements which comprise the Balance Sheet, the Statement of Changes in Equity and the related notes:

The directors approve these financial statements and confirm that they are responsible for them, including selecting the appropriate accounting policies, applying them consistently and making, on a reasonable and prudent basis, the judgements underlying them. They have been prepared on the going concern basis on the grounds that the company will continue in business.

The directors confirm that they have made available to BFGD, (Chartered Accountants), all the company's accounting records and provided all the information, books and documents necessary for the compilation of the financial statements.

The directors confirm that to the best of their knowledge and belief, the accounting records reflect all the transactions of the company for the financial year ended 31 March 2025."

Signed on behalf of the board

John Byrne
Director

14 January 2026

Emily Bredin
Director

14 January 2026

Crumlin Road Pharmacy Limited

BALANCE SHEET

as at 31 March 2025

	Notes	2025 €	2024 €
Fixed Assets			
Tangible assets	7	<u>794,597</u>	<u>785,603</u>
Current Assets			
Stocks	8	187,671	136,000
Debtors	9	269,473	1,367,181
Cash and cash equivalents		298,879	110,576
		<u>756,023</u>	<u>1,613,757</u>
Creditors: amounts falling due within one year	10	<u>(1,033,917)</u>	<u>(350,273)</u>
Net Current (Liabilities)/Assets		<u>(277,894)</u>	<u>1,263,484</u>
Total Assets less Current Liabilities		<u>516,703</u>	<u>2,049,087</u>
Creditors:			
amounts falling due after more than one year	11	<u>(188,154)</u>	<u>(152,725)</u>
Net Assets		<u><u>328,549</u></u>	<u><u>1,896,362</u></u>
Capital and Reserves			
Called up share capital presented as equity		3	3
Retained earnings		328,546	1,896,359
Equity attributable to owners of the company		<u><u>328,549</u></u>	<u><u>1,896,362</u></u>

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

We as Directors of Crumlin Road Pharmacy Limited, state that -

- (a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,
- (b) the company is availing itself of the exemption on the grounds that the conditions specified in section 359 are satisfied,
- (c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),
- (d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,
- (e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 14 January 2026 and signed on its behalf by:

John Byrne
Director

Emily Bredin
Director

Crumlin Road Pharmacy Limited
STATEMENT OF CHANGES IN EQUITY

as at 31 March 2025

	Called up share capital €	Retained earnings €	Total €
At 1 April 2023	3	1,779,914	1,779,917
Profit for the financial year	-	116,445	116,445
At 31 March 2024	3	1,896,359	1,896,362
Profit for the financial year	-	182,187	182,187
Payment of dividends	-	(1,750,000)	(1,750,000)
At 31 March 2025	3	328,546	328,549

Crumlin Road Pharmacy Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 March 2025

1. General Information

Crumlin Road Pharmacy Limited is a private company limited by shares incorporated and registered in Ireland. The registered number of the company is 535503. The registered office of the company is 251 Crumlin Road, Dublin 12 which is also the principal place of business of the company. The principal activity of the company is to carry out the trade of a retail pharmacy. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company financial statements.

Statement of compliance

The financial statements of the company for the year ended 31 March 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

Turnover

Turnover is measured at the fair value of the consideration received or receivable net of VAT and trade discounts.

Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Land and buildings freehold	-	2% straight line
Fixtures, fittings and equipment	-	25% / 12.5% straight line

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Leasing and hire purchases

Tangible assets held under leasing and Hire Purchases arrangements which transfer substantially all the risks and rewards of ownership to the company are capitalised and included in the Balance Sheet at their cost or valuation, less depreciation. The corresponding commitments are recorded as liabilities. Payments in respect of these obligations are treated as consisting of capital and interest elements, with interest charged to the Profit and Loss Account.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing stock to its present location and condition. Cost is calculated using the first-in, first-out formula. Provision is made for damaged, obsolete and slow-moving stock where appropriate.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Crumlin Road Pharmacy Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 March 2025

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Government grants

Capital grants received and receivable are treated as deferred income and amortised to the Profit and Loss Account annually over the useful economic life of the asset to which it relates. Revenue grants are credited to the Profit and Loss Account when received.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

3. Operating profit	2025	2024
	€	€
Operating profit is stated after charging/(crediting):		
Depreciation of tangible assets	36,342	39,964
Government grants received	(12,361)	-
	<u><u> </u></u>	<u><u> </u></u>
4. Interest payable and similar expenses	2025	2024
	€	€
Interest	(12,747)	11,390
	<u><u> </u></u>	<u><u> </u></u>
5. Employees		
The average monthly number of employees, including directors, during the financial year was 12, (2024 - 11).		
6. Dividends	2025	2024
	€	€
Dividends on equity shares:		
Ordinary Shares - Final paid	1,750,000	-
	<u><u> </u></u>	<u><u> </u></u>

Crumlin Road Pharmacy Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 March 2025

7. Tangible assets

	Land and buildings freehold €	Fixtures, fittings and equipment €	Total €
Cost			
At 1 April 2024	729,208	228,403	957,611
Additions	11,511	33,825	45,336
	<u>740,719</u>	<u>262,228</u>	<u>1,002,947</u>
Depreciation			
At 1 April 2024	71,471	100,537	172,008
Charge for the financial year	14,834	21,508	36,342
	<u>86,305</u>	<u>122,045</u>	<u>208,350</u>
Net book value			
At 31 March 2025	<u>654,414</u>	<u>140,183</u>	<u>794,597</u>
At 31 March 2024	<u>657,737</u>	<u>127,866</u>	<u>785,603</u>

8. Stocks

	2025 €	2024 €
Finished goods and goods for resale	<u>187,671</u>	<u>136,000</u>

The replacement cost of stock did not differ significantly from the figures shown.

9. Debtors

	2025 €	2024 €
Trade debtors	182,284	161,341
Amounts owed by group undertakings	4,325	1,106,940
Taxation	79,163	94,952
Prepayments	3,701	3,948
	<u>269,473</u>	<u>1,367,181</u>

10. Creditors Amounts falling due within one year

	2025 €	2024 €
Amounts owed to credit institutions	64,120	57,935
Trade creditors	223,821	162,960
Amounts owed to group undertakings	616,680	-
Taxation	11,345	56,000
Directors' current accounts (Note 14)	135	1,227
Other creditors	5,402	2,720
Accruals	112,414	69,431
	<u>1,033,917</u>	<u>350,273</u>

Crumlin Road Pharmacy Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 March 2025

11. Creditors	2025	2024
Amounts falling due after more than one year	€	€
Bank loan	<u>188,154</u>	<u>152,725</u>
Loans		
Repayable in one year or less, or on demand	64,120	57,935
Repayable between one and two years	128,239	57,935
Repayable between two and five years	59,915	94,790
	<u>252,274</u>	<u>210,660</u>
12. Profit and loss account		
	2025	2024
	€	€
At 1 April 2024	1,896,359	1,779,914
Profit for the financial year	182,187	116,445
Payment of dividends	(1,750,000)	-
At 31 March 2025	<u>328,546</u>	<u>1,896,359</u>
13. Capital commitments		
The company had no material capital commitments at the financial year-ended 31 March 2025 (2024: Nil).		
14. Directors' remuneration and transactions	2025	2024
	€	€
Remuneration	225,710	179,543
Pension contributions	143,831	43,382
	<u>369,541</u>	<u>222,925</u>
The following amounts are repayable to the directors:		
	2025	2024
	€	€
John Byrne	<u>135</u>	<u>1,227</u>
15. Related party transactions		
The company has availed of the exemption under FRS 102 Section 1A in relation to the disclosure of transactions with group undertakings.		
16. Parent company		
The company regards Jabcel Investments Limited as its parent company.		
17. Controlling interest		
The company is under the control of the director John Byrne.		
18. Post-Balance Sheet Events		
There have been no significant events affecting the company since the financial year-end.		

Crumlin Road Pharmacy Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
for the financial year ended 31 March 2025

19. Approval of financial statements

The financial statements were approved and authorised for issue by the board of directors on 14 January 2026.